Connect with us

General Pharmaceuticals

Orexo Hosts Capital Markets Day Today in Stockholm, Sweden

Vlad Poptamas

Published

on

Photo source: youtube.com / Hoosier Tim's Travel Videos
Reading Time: 2 minutes

 

Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, is today hosting the Company’s Capital Markets Day for investors, analysts and media in Stockholm, Sweden.

Orexo’s management team will expand on new strategic initiatives building upon the Company’s strong financial and operational foundation, primarily driven by the performance for Zubsolv® in the US. The event will highlight the Company’s plans to further strengthen its pipeline and innovative formulation technologies. In addition, management will also elaborate on efforts to broaden the commercial platform to leverage scale and expand sales through business development and potentially M&A transactions.

With a highly positive outcome in the recent patent litigation concerning Zubsolv, Orexo’s core asset has received strengthened IP in the US until 2032. The decision has enabled Orexo to continue with its strategy to maximise Zubsolv´s potential in a fast growing US market. The team will also expand on the latest market trends and demonstrate how it intends to further strengthen its market position.

The event will be moderated by Charlotte Stjerngren, former news anchor for Börslunch, where members of the Orexo management team including among others Nikolaj Sørensen, CEO and President, Robert DeLuca, President US Inc., Johannes Doll, EVP and Head of Corporate Development, and Martin Nicklasson, Chairman of the Board of Directors will be presenting. The Keynote speaker is former New Jersey governor, Chris Christie, who will be discussing the current landscape of the opioid crisis, and how to combat it.

All presenters during the Orexo Capital Markets Day

  • Martin Nicklasson, Chairman of the Board of Directors, Orexo
  • Nikolaj Sørensen, CEO and President, Orexo
  • Dan Hawkins, Founder & Managing Director, Clarion Healthcare
  • Robert A. DeLuca, President, Orexo US Inc.
  • Joseph DeFeo, EVP and Chief Financial Officer, Orexo
  • Fred Nyberg, PhD, Professor, Division of Biological Research on Drug Dependence, Uppsala University
  • Johannes Doll, EVP and Head of Corporate Development, Orexo
  • Michael Sumner, Chief Medical Officer, Orexo
  • Robert Rönn, Head of Pharmaceutical Development and IP, Orexo
  • Chris Christie, Former Governor of New Jersey and former Chairman of the US President’s Commission on Combating Drug Addiction and the Opioid Crisis

Event details

The meeting will be held at the Armémuseet, Riddargatan 13, Stockholm, Sweden. The event will start at 12:00 noon CET with a networking lunch, followed by presentations commencing at
1:00 pm CET.

A live webcast will be available on the Orexo website and questions related to the presentations can also be sent to ir. A replay of the event and presentation slides, excluding Chris Christie´s performance, will be made available shortly after.

Hello!


Thank you for visiting my profile and thank you for reading my news and published press release!


There a many things that shape a man, but the carving is done by the hobbies and passions. I've pursued two main careers, professional photography and webdesign, while also keeping a passion for automobiles, technology and games. At PICANTE NEWS, I take care of news editing and press release publishing in se
veral categories and as I've mentioned, during my spare time, I am also a professional photographer with webdesign skills.

My future plans include developing more journalistic skills and start creating investigative journalism. You can find my reports and press release coverages in the following categories:


BANKING/FINANCIAL SERVICES, COMPUTER ELECTRONICS, AUTOMOTIVE, CONTRACTS, ANALYSIS, INTERNET TECHNOLOGY, BIOTECHNOLOGY, BLOCKCHAIN, ACQUISITIONS, RETAIL, and many more.



You can get in touch to discuss interviews or possible article submissions by contacting us.


Let's also connect via social media! You can find me on Facebook or visit my photo portfolio.

Advertisement
Comments

Computer Electronics

Innovate and Win the Future through Intelligence, P-MEC China 2019 to “Set Sail” Intelligently

Vlad Poptamas

Published

on

Photo source: tradeshows.tradeindia.com
Reading Time: 3 minutes

 

The National Medical Products Administration of China officially issued the Guiding Opinions on Building Information Technology-Enabled Drug Traceability Systems in Nov. 2018. The introduction of this Guiding Opinions marks the return of the drug traceability system after the electronic supervision code system was halted in 2016. Tracking and source tracing of information in pharmaceutical production, circulation, and use, etc. through information-technology-enabled means to form an organic whole will become a development trend of the industry in the future. Chinese pharmaceutical enterprises have attached greater importance to the improvement of enterprise information management as successive favorable policies are introduced.

P-MEC China 2019, a grand international party for the industry exchange and cooperation, and common development in the pharmaceutical field that is hosted by China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE) and UBM EMEA and co-sponsored by Shanghai UBM Sinoexpo International Exhibition Co., Ltd. (UBM Sinoexpo), will “set sail” intelligently on June 18-20, 2019 at Shanghai New International Expo Centre. The exhibition will further upgrade and optimize the Pharma Automation & Information Zone first launched in 2018 – it will be located in Hall N1 to co-locate with global leading pharmaceutical equipment manufacturers. The “Automation and Informatization Forum” will also be held concurrently, to provide pharmaceutical enterprises and pharmaceutical equipment enterprises with an efficient platform for display, exchange, cooperation, and learning.

To help the Chinese pharmaceutical producers welcome the new era of intelligent production

Tang Jiliang, a former researcher of Shanghai Institute of Pharmaceutical Industry, said in an interview, “The real intelligent manufacturing can effectively shorten product development, increase production efficiency, improve product quality, and reduce resource and energy consumption. All those advantages are what traditional pharmaceutical industry lacks and urgently needs. In the coming years, intelligent manufacturing will become a development trend of the global pharmaceutical industry that serves as a part of the manufacturing industry.”

P-MEC China is a prestigious event of the pharmaceutical engineering and machinery industry in China and Asia-Pacific region. The host, in order to accurately show the current situation of pharmaceutical automation and informatization in China and assist pharmaceutical enterprises to achieve compliant and efficient development, will make every effort to increase promotion of the Pharma Automation & Information Zone in 2019, so as to attract industry top enterprises to join. The zone will cover three aspects: system integration (providing overall project solutions and implementation schemes), automatic products (robots, manipulators, mechanical transmission products, AGV automatic logistics equipment and systems, mechanical lifting and handling equipment, packaging and sorting products, sensors, controllers, inverters, and instruments and valves, etc.), and information system (MES, ERP system, cGMP management system, CaaS, IDC-internet data center, and industrial big data service), to give visitors a close look at the leading techniques in the global intelligent manufacturing field.

To focus on the pharmaceutical intelligent manufacturing and achieve upgrading and transformation of traditional industry

Besides the product display, there will be a 1.5-day “Automation and Informatization Forum” held in the Pharma Automation & Information Zone, to directly touch upon core elements of pharmaceutical intelligent manufacturing. The host will invite international top technology providers and representatives of Chinese leading pharmaceutical enterprises, to share and discuss the most popular information applications presently in use as well as automatic production process upgrading, bringing visitors a deluge of intelligent knowledge. The forum will cover fascinating topics including “Multi-place Coordinated Production of Pharmaceutical Enterprises based on Digitalization and Informatization”, “From R&D to Production–How to Largely Increase Efficiency through Transparent and Complete Information Data”, “A Focus on Pharma 4.0–What Do We Lack for Achieving Intelligent Pharma?”, and “How to Achieve Robustness Improvement of the Production Process through Perfection of Data Integrity”.

What P-MEC China 2019 will bring is not only the application of global intelligent technology in the pharmaceutical industry, but also an important step in leading the Chinese and even Asian pharmaceutical industry towards comprehensive intelligent manufacturing.

For more information, please visit the official website: http://en.pmecchina.com/

Continue Reading

Clinical Trials & Medical Discoveries

CSA Medical’s truFreeze® Spray Cryotherapy Highlighted at New York Society for Gastrointestinal Endoscopy Annual Me eting 2018

Vlad Poptamas

Published

on

Reading Time: 2 minutes

 

Spray Cryotherapy Ablation procedure shared “live” and in real time demonstrates the use of Rapid AV Catheter in Esophageal Cancer

CSA Medical announced the first live case highlighting the use of the company’s truFreeze® Spray Cryotherapy in a patient with esophageal cancer that was performed yesterday during a Live Case presentation at the 42nd Annual New York Course of the New York Society for Gastrointestinal Endoscopy (NYSGE). Vanessa M. Shami, MD, professor of gastroenterology at the University of Virginia Medical Center, successfully performed the procedure which was streamed live on December 13, 2018.

truFreeze utilizes the extreme cold of liquid nitrogen (-196 C) to ablate diseased tissue, including cancer, causing instant cell death. Together with a 16 Fr. CryoDecompression Tube, clinicians are able to get into constricted spaces, a characteristic of esophageal cancer. Moreover, truFreeze does not require the catheter to touch the tissue, enabling the treatment of nodular disease and unique morphologies.

“The inability to swallow and eat a normal diet significantly decreases the quality of life for patients with esophageal cancer, and can result in malnutrition,” said Dr. Shami. “I recommend spray cryotherapy ablation to many of my esophageal cancer patients because it penetrates deeper than other ablation therapies without the scarring and post-procedural pain associated with radiofrequency burning or balloon ablation. The ability to perform the procedure as an outpatient therapy that allows patients to go home the same day provides significant quality of life benefits to a population that may be suffering from a range of health challenges.”

The patient, in his 90s, had a recurrent tumor and is not a candidate for surgery. He opted for spray cryotherapy ablation of the tumor based on data demonstrating that this approach could improve his ability to swallow and eat a more normal diet without the foreign body sensation associated with stents. To date, the patient has undergone two treatments approximately one month apart and was able to return home the same day without the need for narcotics. Additionally, he did not report any noticeable side effects following each procedure.

“truFreeze spray cryotherapy is rigorously tested and widely adopted and is the only FDA-cleared therapy proven to treat the entire esophageal disease spectrum, including esophageal cancer. For the patient, there is also data that supports spray cryotherapy resulting in less pain than other ablative therapies,” said Wendelin Maners, CSA’s President, truFreeze Business. “Dr. Shami’s live procedure underscored not only truFreeze’s ease of use, but also the important quality of life improvements that spray cryotherapy can achieve for this patient population. We hope that today’s demonstration will remind gastroenterologists to incorporate truFreeze into their treatment algorithm for both Barrett’s esophagus and esophageal cancer patients.”

Continue Reading

Computer Electronics

Sun Nuclear Releases 1028 XP Continuous Radon Monitor

Vlad Poptamas

Published

on

Reading Time: 2 minutes

 

Sun Nuclear Corporation, a leading provider of Continuous Radon Monitors (CRMs) for commercial and residential purposes, today announced release of the 1028™ XP Continuous Radon Monitor. The 1028 XP is the latest offering from the Sun Nuclear Radon Detection product line.

The 1028 XP Monitor takes the trusted technology of the Model 1028™ CRM and expands on it with a full-color graphic display for comprehensive review of data and test results, an extended battery life of up to 300 hours, and 10,000 datapoints in up to 10 test memory slots. Its Bluetooth connectivity to the OneRADON reporting software, make it a great solution for radon professionals on the go.

“We’re excited to offer this new Monitor to our customers, based on the trusted technology of our Model 1028 monitor,” said Dr. Kai Wundke, Sun Nuclear’s Senior Director, Radon. “The modern, functional design and easy-to-use interface combined with its expandable capabilities make it a smart investment for radon professionals.”

A future, modular upgrade to the 1028 XP and OneRADON Software will support cellular communication for remote operation and cloud connectivity. It will also support environmental monitoring of Volatile Organic Compounds (VOCs), Carbon Dioxide, temperature, pressure, and humidity.

In addition to this new Monitor, Sun Nuclear offers Model 1027™, Model 1028™, and Model 1030™ CRMs for professional home and building inspectors. The Model 1030 recently received National Radon Safety Board (NRSB) approval.

About Sun Nuclear Corporation
In addition to providing leading Radon Detection solutions for commercial and residential purposes, Sun Nuclear is the worldwide leader in Patient Safety solutions for Radiation Oncology. We design and manufacture devices and software to ensure radiation prescriptions are accurately and consistently delivered to cancer patients. We hold numerous patents for groundbreaking product designs, and distribute solutions globally, both directly and through a network of 60+ distributors. Gammex, a leader in patient alignment technology and QA tools for the diagnostic radiology field, is a wholly-owned subsidiary. Visit us: sunnuclear.com. Follow us: @SNC_Radon.

Continue Reading

Font Resizer

Subscribe to PICANTE via Email

Enter your email address to subscribe to PICANTE and receive notifications of new posts by email.

Follow us on Facebook

Read more from our authors

Business Wire2 hours ago

XINHUANET: Promotion Event of The Most Beautiful Shooting Location in China Held During Cannes Film Festival

Business Wire9 hours ago

GEICO’s Tips for Sharing the Road with Motorcycles

Business Wire13 hours ago

Paramount Pictures Hosted Free 25th Anniversary Screening of Academy Award®-Winning Classic FORREST GUMP on National Mall

Business Wire17 hours ago

NUTANIX 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Nutanix, Inc. – NTNX

Business Wire17 hours ago

MCDONALD’S INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of McDonald’s Corporation – MCD

Business Wire17 hours ago

XPO LOGISTICS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of XPO Logistics, Inc. – XPO

Business Wire17 hours ago

AMERICAN RENAL 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against American Renal Associates Holdings, Inc. – ARA

Business Wire17 hours ago

SUPER MICRO INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Super Micro Computer, Inc. – SMCI

Business Wire17 hours ago

PFIZER INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Pfizer Inc. – PFE

Business Wire18 hours ago

Glancy Prongay & Murray LLP Announces Investigation on Behalf of Floor & Decor Holdings, Inc. Investors (FND)

Follow our Tweets

Trending

Please turn AdBlock off